Eurofarma

Eurofarma, formally Eurofarma Laboratórios S.A., is a Brazilian pharmaceutical manufacturer and healthcare group founded in 1972. The company has developed from a domestic medicines producer into one of the largest pharmaceutical businesses in Brazil and Latin America, while remaining controlled by Brazilian private capital. Its activities span the development, manufacture and commercialization of medicines and related healthcare products rather than being limited to a single therapeutic specialty. The group operates across several principal pharmaceutical segments. These include medical-prescription products, generic medicines, over-the-counter products, hospital medicines, oncology products, veterinary medicines, exports and contract or outsourced pharmaceutical manufacturing. In Brazil, Eurofarma offers more than 2,000 products, serving dozens of medical specialties and more than 140 therapeutic classes. Its portfolio therefore combines branded and generic medicines with products targeted at consumers, physicians, hospitals and animal-health customers. Eurofarma has expanded through a mixture of organic investment, international operating subsidiaries, manufacturing infrastructure and acquisitions. Its manufacturing and commercial footprint extends throughout Latin America, with operations or facilities in countries including Argentina, Bolivia, Chile, Colombia, Ecuador, Guatemala, Mexico, Paraguay, Peru, Uruguay and Venezuela, as well as a presence in Mozambique and the United States. Reference material describes the group as active in 22 countries and covering the Latin American region broadly, although the precise country count and operating configuration may change over time. A major step in the company's international development came in 2023, when it completed the acquisition of Genfar, Sanofi's generics business headquartered in Colombia and operating with affiliates in Ecuador and Peru. Eurofarma also acquired seven Sanofi assets serving Brazil, Colombia, Mexico, Argentina and Uruguay. These transactions strengthened its generic-medicine platform and expanded its portfolio across important Latin American markets. Eurofarma has also participated in large-scale pharmaceutical manufacturing partnerships. In August 2021, Pfizer and BioNTech announced an agreement under which Eurofarma would manufacture doses of the COMIRNATY COVID-19 vaccine in Brazil from 2022, with the intended output directed to Latin American and Caribbean markets. The arrangement was associated with broader regional vaccine-supply efforts involving public-health institutions and the COVAX mechanism. The group combines manufacturing and research activity with a substantial commercial organization. Its sales and medical-promotion workforce supports relationships with healthcare professionals, pharmacies, hospitals and other customers. Reference material states that Eurofarma generated net sales of R$9.1 billion in 2023, employed more than 12,000 people and invested R$680 million during that year; these figures are reported for 2023 and should not be treated as current without updated company disclosure. The same material describes a development pipeline of more than 350 projects. Beyond healthcare, Eurofarma has built visibility through long-term sports sponsorship. It has supported Stock Car Brasil for nearly two decades through the Eurofarma-RC team, sponsored the NBB All-Star Game and supported racing drivers including Enzo Fittipaldi and Pietro Fittipaldi. These activities complement the company's corporate and product presence by associating the brand with Brazilian motorsport and broader regional sports audiences.

Eurofarma was established in Brazil in 1972 and grew within the country's pharmaceutical market before developing a broader multinational structure. Its core model has combined pharmaceutical production with the commercialization of medicines across multiple healthcare channels. Rather than concentrating exclusively on either innovative drugs or low-cost generics, the group has maintained a diversified portfolio spanning prescription products, consumer medicines, hospital therapies, oncology and veterinary healthcare. Brazil became the company's principal operating base and remains central to its identity. The group built a large domestic portfolio, with reference material describing more than 2,000 products sold in Brazil across approximately 42 medical specialties and more than 140 therapeutic classes. This breadth has supported relationships with physicians, hospitals, pharmacies and consumers, while its commercial organization has helped make medical promotion an important part of the business model. International expansion became a defining phase of Eurofarma's development. The group established manufacturing and commercial operations across Latin America, including in Argentina, Bolivia, Chile, Colombia, Ecuador, Guatemala, Mexico, Paraguay, Peru, Uruguay and Venezuela. It also developed activity in Mozambique and the United States. The resulting network gives Eurofarma a regional rather than solely national profile and supports exports, local production and the distribution of pharmaceutical products in multiple markets. The company has used acquisitions to accelerate this regional strategy. In 2023 it completed the acquisition of Genfar, Sanofi's generics operation headquartered in Colombia, including affiliates in Ecuador and Peru. It also acquired seven Sanofi assets associated with Brazil, Colombia, Mexico, Argentina and Uruguay. These transactions expanded Eurofarma's generic portfolio and added products and commercial capabilities in several of the group's priority markets. Eurofarma's manufacturing role extended beyond its own portfolio through its 2021 agreement with Pfizer and BioNTech. Under the partnership, the Brazilian company was selected to manufacture COMIRNATY COVID-19 vaccine doses from 2022, with at least 100 million annual doses contemplated for regional distribution. The agreement formed part of wider efforts to increase vaccine availability in Latin America and the Caribbean. The group has continued to invest in production, product development and international growth. Reference material reports that Eurofarma invested R$680 million in 2023 and had a pipeline exceeding 350 projects. It also reports 2023 net sales of R$9.1 billion and a workforce of more than 12,000 employees. These are historical figures for the stated year, not an assertion of current performance. Brand-building has included sustained sports marketing. Eurofarma has sponsored Stock Car Brasil for many years and operates the Eurofarma-RC team, with Ricardo Maurício associated with the team since 2009 and becoming a three-time champion in 2020. The company has also sponsored the NBB All-Star Game and supported drivers Enzo Fittipaldi and Pietro Fittipaldi. In 2024, Eurofarma branding appeared on Pietro Fittipaldi's RLL No. 30 IndyCar at Laguna Seca, visually linking the international racing program to the Eurofarma-RC identity. Today, Eurofarma is best understood as a privately controlled Brazilian pharmaceutical group with a broad product base, a large Latin American operating footprint and ambitions extending into additional international markets. Its principal strategic themes are portfolio diversification, generic-medicine scale, manufacturing capability, acquisitions and regional access to healthcare.

• 2024

  Nineteenth consecutive year of Stock Car sponsorship

  [1]Eurofarmaen.wikipedia.org

  The company reaches 19 uninterrupted years of sponsorship in Stock Car Brasil.

• 2023

  Genfar and Sanofi asset acquisitions completed

  [1]Eurofarmaen.wikipedia.org

  Eurofarma completes the acquisition of Genfar and seven additional Sanofi assets in Latin American markets.

• 2021

  COVID-19 vaccine manufacturing partnership announced

  [1]Eurofarmaen.wikipedia.org

  Pfizer and BioNTech select Eurofarma to manufacture COMIRNATY doses in Brazil for regional distribution from 2022.

• 2005

  Stock Car Brasil sponsorship begins

  [1]Eurofarmaen.wikipedia.org

  Eurofarma begins its long-running involvement with Stock Car Brasil, later associated with the Eurofarma-RC team.

• 1972

  Eurofarma is founded in Brazil

  [1]Eurofarmaen.wikipedia.org

  Eurofarma begins operations as a Brazilian pharmaceutical company.

A diversified Brazilian pharmaceutical and healthcare group positioned around broad therapeutic coverage, generic and branded medicines, regional Latin American expansion, manufacturing scale and access to healthcare.

• Pharmaceuticals

  Generic medicines

  Generic medicines are a central part of Eurofarma's portfolio and international growth strategy. The company produces and markets generic products across numerous therapeutic classes, serving pharmacies, physicians, hospitals and public or private healthcare systems. Its 2023 acquisition of Genfar strengthened this platform in Colombia, Ecuador and Peru.

• Pharmaceuticals

  Prescription medicines

  Eurofarma's medical-prescription portfolio covers a broad range of specialties and therapeutic areas. These products are promoted through the group's medical and commercial organization and form a substantial part of its Brazilian and Latin American healthcare business.

• Consumer healthcare

  Over-the-counter medicines

  The over-the-counter segment gives Eurofarma a direct consumer-health presence alongside its prescription business. Products in this category are marketed through retail pharmacy and other consumer channels, although the available reference material does not identify a complete product list.

• Specialty pharmaceuticals

  Hospital and oncology medicines

  Eurofarma operates in hospital and oncology pharmaceuticals, serving institutional and specialist-care settings. These businesses complement its high-volume generic and prescription activities with products requiring closer engagement with hospitals, specialists and healthcare systems.

• Animal health

  Veterinary medicines

  Veterinary medicines extend Eurofarma's healthcare activities into animal health. The reference material identifies veterinary products as part of the group's offering but does not provide sufficient detail to enumerate individual brands or therapeutic categories.

• Vaccine manufacturing · 2022

  COMIRNATY manufacturing

  Under its partnership with Pfizer and BioNTech, Eurofarma was selected to manufacture COMIRNATY COVID-19 vaccine doses in Brazil for distribution in Latin America and the Caribbean. This was a manufacturing partnership rather than a Eurofarma-originated vaccine brand.

• 2024Fittipaldi racing sponsorship

  Brazil · United States · International

  Eurofarma sponsored Enzo Fittipaldi in Formula 2 and Pietro Fittipaldi in IndyCar. At the 2024 Laguna Seca event, Pietro's RLL No. 30 car received Eurofarma-themed livery and apparel.

  Outcome. The activation extended Eurofarma's motorsport identity beyond Brazil and connected its international racing sponsorship to the Eurofarma-RC visual design.

  Source
• 2020Eurofarma-RC motorsport program

  Brazil

  Eurofarma promoted its brand through the Eurofarma-RC team in Stock Car Brasil. Ricardo Maurício, who had represented the team since 2009, won his third championship in 2020.

  Outcome. The result reinforced the association between Eurofarma and competitive Brazilian motorsport.

  Source
• 2005Stock Car Brasil sponsorship

  Brazil

  Eurofarma began a long-term sponsorship presence in Stock Car Brasil and later maintained its own Eurofarma-RC team. The program has been one of the company's most visible brand-building activities in Brazil.

  Outcome. The sponsorship continued for 19 uninterrupted years by 2024, linking the pharmaceutical brand with Brazilian motorsport.

  Source
• NBB All-Star Game sponsorship

  Brazil

  Eurofarma has also sponsored the NBB All-Star Game, broadening its sports-marketing activity from motorsport into Brazilian basketball.

  Source

• 2023

  Acquire Genfar and additional Sanofi assetsM&A

  Background

  Eurofarma pursued greater scale in generic medicines and broader coverage of Latin American markets.

  Action taken

  The group completed the acquisition of Genfar, Sanofi's Colombia-headquartered generics operation with affiliates in Ecuador and Peru, and acquired seven additional Sanofi assets serving Brazil, Colombia, Mexico, Argentina and Uruguay.

  Aftermath

  The transactions expanded Eurofarma's portfolio, geographic footprint and position in Latin American generic medicines.

  Source

• 2021

  Enter COVID-19 vaccine manufacturing partnershipOther

  Background

  Pfizer and BioNTech sought additional regional manufacturing capacity for their COVID-19 vaccine and announced Eurofarma as a Brazilian production partner.

  Action taken

  Eurofarma agreed to manufacture COMIRNATY doses in Brazil from 2022, with planned distribution to Latin American and Caribbean markets.

  Aftermath

  The agreement positioned Eurofarma within regional vaccine-supply and COVAX-related capacity-building efforts.

  Source

1. 1Eurofarmaen.wikipedia.org